Yao, L. Sun, J. Hu, L. Chen, J. Zhang, J. Xu, Y. Xie, Y#. Ovarian cancer risk of Chinese women with BRCA1/2 germline pathogenic variants,Journal of human genetics,67(11):639-42

Tan, Y. Yao, L. Gamliel, A. Nair, S. J. Taylor, H. Ohgi, K. Aggarwal, A. K. Rosenfeld, M. G*. Signal-induced enhancer activation requires Ku70 to read topoisomerase1-DNA covalent complexes,Nat Struct Mol Biol,30(2):148-58

Zang, F#. Ding, X#. Chen, J. Hu, L. Sun, J. Zhang, J. Xu, Y. Yao, L*. Xie, Y*. Prevalence of BRCA1 and BRCA2 pathogenic variants in 8627 unselected patients with breast cancer: stratification of age at diagnosis, family history and molecular subtype,Breast Cancer Res Treat,195(3):431-9

Liu X#, Wang Y#, Cao K#, Yao L#, Hu L, Sun J, Zhang J, Xu Y, Xie Y*. Impact of multifocal or multicentric disease on local recurrence and survival in breast cancer patients with or without BRCA1/2 variants,Breast Cancer Res Treat,199(1):25-33

Zhang, J#. Yao, L#. Liu, Y. Ouyang, T. Li, J. Wang, T. Fan, Z. Fan, T. Lin, B. Xie, Y*. Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer,Int J Cancer,2021.148: 941-9

Meng, H#. Yao, L#. Yuan, H#. Xu, Y. Ouyang, T. Li, J. Wang, T. Fan, Z. Fan, T. Lin, B. Xie, Y*. BRCA1 c.5470_5477del, a founder mutation in Chinese Han breast cancer patients,Int J Cancer,2020. 146: 3044-52

Fu, F#. Zhang, D#. Hu, L#. Sundaram, S. Ying, D. Zhang, Y. Fu, S. Zhang, J. Yao, L. Xu, Y. Xie, Y*. Association between 15 known or potential breast cancer susceptibility genes and breast cancer risks in Chinese women,Cancer Biol Med,

Sheng, S. Xu, Y. Guo, Y. Yao, L. Hu, L. Ouyang, T. Li, J. Wang, T. Fan, Z. Fan, T. Lin, B. Xie, Y.* Prevalence and clinical impact of TP53 germline mutations in Chinese women with breast cancer,Int J Cancer,2020.146(2):487-495

家族遗传性乳腺癌

BARD1胚系突变在乳腺癌DNA损伤应答中的作用及潜在临床意义, 课题负责人, 2023.1.1～2026.12.31, 国家自然科学基金面上项目

中国人群特异BRCA1/2重复突变的乳腺癌发病风险评估及功能研究, 课题负责人, 2017.1.1～2020.12.31, 国家自然科学基金面上项目

DNA修复基因致病性突变对乳腺癌新辅助化疗疗效的预测作用, 课题负责人, 2021.1.1～2023.12.31, 北京市医管局培育项目

中国家族性乳腺癌BRCA1/2基因大片段重排断裂位点鉴定及功能研究, 参加者, 2018.1.1～2021.12.31, 国家自然科学基金面上项目

研究生招生计划

招生年度	招生专业	学位级别	学位类型	研究方向	选拔方式	操作
2024	肿瘤学	硕士	科学学位	遗传性乳腺癌	推荐免试